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Abstract
Background
Neurodegenerative Langerhans Cell Histiocytosis (ND-LCH) is a rare, unpredictable conse-
quence that may devastate the quality of life of patients cured from LCH. We prospectively
applied a multidisciplinary diagnostic work-up to early identify and follow-up patients with
ND-LCH, with the ultimate goal of better determining the appropriate time for starting
therapy.
Methods
We studied 27 children and young adults with either ND-LCH verified by structural magnetic
resonance imaging (MRI) (group 1) or specific risk factors for (diabetes insipidus, craniofa-
cial bone lesions), but no evidence of, neurodegenerative MRI changes (group 2). All
patients underwent clinical, neurophysiological and MRI studies.
Results
Seventeen patients had MRI alterations typical for ND-LCH. Nine showed neurological
impairment but only three were symptomatic; 11 had abnormal somatosensory evoked
potentials (SEPs), and five had abnormal brainstem auditory evoked potentials (BAEPs).
MR spectroscopy (MRS) showed reduced cerebellar NAA/Cr ratio in nine patients. SEPs
showed sensitivity, specificity, positive predictive value (PPV) and negative predictive value
(NPV) for predicting ND-LCH of 70.6% (95%CI, 44.0%-89.7%), 100% (69.2%-100%), 100%
(73.5%-100%), and 66.7% (38.4%-88.2%), respectively. Repeated investigations in group
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1 revealed increasingly abnormal EP parameters, or neurological examination, or both, in
nine of fifteen patients while MRI remained unchanged in all but one patient.
Conclusion
A targeted MRI study should be performed in all patients with risk factors for ND-LCH for
early identification of demyelination. The combined use of SEPs and careful neurological
evaluation may represent a valuable, low-cost, well-tolerated and easily available methodol-
ogy to monitor patients from pre-symptomatic to symptomatic stages. We suggest a multi-
disciplinary protocol including clinical, MRS, and neurophysiological investigations to
identify a population target for future therapeutic trials.
Introduction
Langerhans cell histiocytosis (LCH) is a rare disease of the dendritic cell system that may occur
at any age, with a peak incidence between 5 and 10 years[1]. Its annual incidence has been esti-
mated to be one case in 200.000 subjects at risk in two independent studies in France[2] and in
Japan[3]. Its histopathologic landmark is a granulomatous infiltrate of histiocytes of LC pheno-
type (CD1a+), interspersed with varying proportions of macrophages, T-lymphocytes, eosino-
phils and multinucleated giant cells. The mechanisms underlying LCH have not been fully
clarified. The demonstration that lesional Langerhans cells are clonal, along with the recent dis-
covery of activating BRAF mutations in LCH cells, has been taken as a strong support to the
concept that LCH is a neoplastic disease[4, 5]. Clinical presentation and course of LCH are
widely heterogeneous and may range from self-healing isolated skin or bone lesion(s), to dis-
seminated disease with potentially lethal tissue damage[1]. Survivors may experience perma-
nent consequences, which affect the CNS in up to 30% of cases[6, 7].
Different MRI patterns of CNS involvement have been described[8, 9, 10]. The most com-
mon is the hypothalamic-pituitary granuloma, with diabetes insipidus (DI) and anterior pitui-
tary dysfunction. Less frequently granulomatous lesions have been detected in the meninges,
the choroid plexus, the pineal gland or the cerebral parenchyma. The second most frequent
MRI pattern is the “neurodegenerative LCH” (ND-LCH), characterized by bilateral symmetric
alterations of variable signal intensity located in the cerebellar grey matter, sometimes extend-
ing to the underlying white matter, in the basal ganglia and brainstem. Histopathology from
cerebellar biopsies and autopsies revealed neuronal loss, axonal degeneration and a profound
T-cell inflammation[11].
ND-LCH is a potentially devastating, permanent consequence of LCH. Its real prevalence
is still unclear, ranging between 1% and 25% in different cohorts [12–17]. Patients with “cra-
nio-facial” lesions involving the orbital, temporal, sphenoid, ethmoid or mastoid bones, the
paranasal sinuses, the anterior or middle cranial fossa and/or with DI, carry a higher risk of
developing this serious complication[7–18].The pathogenic process might propagate from
long-standing granulomatous lesions of the craniofacial bones to the intracranial space, and
then stimulate a chemokine/cytokine tissue damage or initiate an autoimmune response to
brain components[11].
Despite a relatively homogeneous MRI pattern, the clinical manifestations of ND-LCH are
extremely heterogeneous, ranging from minimal or no neurological impairment, to a severe
clinical picture including ataxia, spastic quadriparesis, intellectual disability and psychiatric
symptoms[9, 12–16]. Although the likelihood of observing clinical manifestations appears to
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be related to the observation time[12], some patients unexpectedly remain asymptomatic for
years despite exhibiting MRI abnormalities[9, 12–17, 19]. Previous attempts to characterize the
clinical and functional pattern of ND-LCH and the progression of this complication have
yielded inconsistent results[15, 19]. Small retrospective studies described global cognitive
impairment with mild memory, attention, and perceptual-organizational changes[13, 19–21].
Abnormal visual (VEPs) and brainstem evoked potentials (BAEPs), and EEG have been
reported in a few patients with ND-LCH[15, 19]. Somatosensory evoked potentials (SEPs)
have been used for characterizing cerebellar and brainstem dysfunction in several neurological
diseases [22–24] but their diagnostic yield has not been assessedin ND-LCH.Thus, there is no
evidence supporting the usefulness of neurophysiological examinations in patients with
ND-LCH. A standardized diagnostic approach able to predict the clinical progression in
patients with ND-LCH might represent a response to an unmet medical need.
Another largely unmet need concerns effective ND-LCH treatment. Various approaches,
including chemotherapy, anti-inflammatory, anti-angiogenic and immune-modulatory medi-
cations, have been used in a few symptomatic patients yielding deceptive results. Based on
these data from sporadic reports, the current prospective therapeutic trial LCH-IV of the His-
tiocyte Society (EudraCT number: 2011-001699-20) suggest either intravenous immune globu-
lin or cytarabine in patients with clinical signs of ND-LCH.
In this study we describe clinical features, MRI and neurophysiological alterations in
ND-LCH and propose a diagnostic work-up for early identification and follow-up of
ND-LCH, with the ultimate goal of selecting patients for a future therapeutic intervention in
pre- or pauci-symptomatic stages.
Methods
Primary and secondary endpoints
Our primary endpoints were: a) to analyze clinical features, MRI and neurophysiological alter-
ations in ND-LCH and b) propose a diagnostic work-up for early identification and follow-up
of ND-LCH. Secondary endpoints were: a) to follow-up a group of patients with ND-LCH and
b) to define selection criteria for a future therapeutic intervention in pre- or pauci-symptomatic
stages.
Study population and diagnostic protocol
As the national referral center for LCH, we launched a survey among all the Italian pediatric
hematology-oncology centers to evaluate patients with LCH, either newly diagnosed, on ther-
apy or in follow-up, using a new integrated diagnostic protocol for ND-LCH. In our study we
defined as affected by ND-LCH all patients showing typical MRI alterations and we considered
structural MRI evaluation as the reference standard[9, 11, 16]. Inclusion criteria were:
informed consent, histologically proven LCH, and presence of risk factors for ND-LCH. Exclu-
sion criteria were: presence of non-LCH related MRI alterations and incomplete MRI protocol.
Risk factors were defined as cranio-facial bone lesions and/or DI at the study entry[18].
The diagnostic protocol included the following steps: neurological examination (NE),
neuropsychological and neurophysiological study (SEPs, BAEPs, VEPs, EEG), MRspectroscopy
(MRS) (see S1 Methods for details). The neuroradiologists who evaluated structural MRI were
blinded to the results of the diagnostic protocol and the physicist who analysed MRS was
blinded to the results of. neuropsychological,neurophysiological, and structural MRI studies.
Neuroradiologists were aware of the results of previous MRI investigations, if any.
Written informed consent was obtained from the parents of affected children or directly
from the patients if they were older than 18 years of age.
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Ethics Statement
The study was approved by the Meyer Children’s University Hospital Ethics Committee in
Florence, Italy and has been performed in accordance with the ethical standards laid down in
the 1964 Declaration of Helsinki and its later amendments.
Data collection and statistical analysis
We stored demographics and data on organ involvement, treatment, and disease course in a
dedicated database. On the basis of the reference standard findings, we classified patients in
two groups: group 1 including patients with ND-LCH and group 2 including patients without
ND-LCH, but at risk to develop it.
The date of onset of LCH was that of either histological diagnosis or onset of isolated DI.
We summarized continuous time variables (age at LCH onset, age at the study entry) by
median and range, and made comparisons between groups using Mann-Whitney test. When
appropriate, confidence intervals (CI) were calculated using exact likelihood. We set level of
significance at 5% two sided.
We analyzed diagnostic accuracy by calculating sensitivity, specificity, Receiver operating
characteristic (ROC) curves, positive and negative predictive values for all the diagnostic tests
included in the protocol.
Considering as outcome the ordinal MRI grading, we evaluated the discrimination perfor-
mance of the diagnostic tests using Harrell’s c, a generalization of the area under the ROC
curve[25, 26].
To evaluate the improvement in discrimination of adding to the best performing diagnostics
a further test, we calculated the Integrated Discrimination Improvement (IDI) statistics[25].
We also reported the components of IDI, i.e. the average improvement in sensitivity for each
level of grading MRI. We conducted all statistical analyses using STATA 12 (T Stat s.r.l.).
Results
Study population (S1 Table, Table 1)
Between April 2010 and February 2012, we enrolled 30 consecutive patients. We subsequentely
excluded three patients because they either did not complete the MRI protocol (n = 2) or
showed brainstem abnormalities of uncertain nature at MRI (n = 1).
Finally, 27 patients (16 males, 11 females) were evaluable for the analysis. Their median age
at the study entry was 8.7 years (range, 1.4 to 27.5; quartiles: 5.3, 8.7, 14.6 years). LCH had been
diagnosed at a median age of 2.9 years (range, 4 months -18 years; quartiles: 1.5, 2.9, 7 years).
Seventeen patients had DI, which was already present at the time of the diagnosis of LCH
(n = 9) or developed during the course (n = 8). Nineteen of the 27 patients had multisystem,
and eight single-system disease. Recurrent or chronic active disease was present in 21 patients
(78%), 24 had received chemotherapy, and 11 of them were being treated during the study.
Median age at the study entry was similar in groups 1 and 2 (8.2 vs. 10.2 years; p = 0.670).
The duration of the disease (time elapsed between the onset of LCH and the first MRI evalua-
tion), did not differ in the two groups (p = 0.688). Patients in group 1 had a significantly youn-
ger age at the onset of LCH than those in group 2 (2 vs. 5.5 years; p = 0.024). Multisystem and
reactivating disease appear to be more frequent in patients in group 1, although failing to reach
the statistical significance (S1 Table and Table 1).
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Reference standard
Neuroimaging (S2 Table). We identified seventeen patients with ND-LCH, ten of whom
had no previous evidence of neurodegenerative alterations. All patients exhibited atypical MRI
pattern with prevalent involvement of the dentate nucleus and the medium cerebellar pedun-
cles (S1 Fig). In six patients cerebellar abnormalities were very mild (grading:1). Signal abnor-
malities were also observed in other sites: supra-tentorial white matter (n = 8), brainstem
(n = 7), and basal ganglia (n = 1). MRS disclosed an abnormal NAA/Cr ratio in the cerebellum
of eight patients of group 1 while was normal in all patients in group 2.
Diagnostic tests
Neurological examination (S2 Table). Neurological examination was abnormal in 10
patients, nine with (group 1) and one without (group 2) ND-LCH, of which seven were subjec-
tively healthy. The Scale for the Assessment and Rating of Ataxia (S.A.R.A) revealed an abnor-
mal score (range, 1–39) in nine, while only pyramidal signs (hyperreflexia, ankle clonus and
Babinski sign) were present in the remaining. Barthel index reached the maximum score (100)
in all patients except two (#7,#15), who scored 3 and 80, respectively.
Neurophysiological assessment (S2 Table). Evoked potentials were performed in all 27
patients. In one patient VEPs were unreliable due to technical reasons. SEPs were abnormal in
11 patients of group 1, bilaterally in six. The N20 response was delayed in four (#1,#8–10), of
decreased amplitude in four (#2,#4,#5,#16), and absent in three (#7,#14,#15) patients. The P14
response was absent in two patients (#7,#15) and of decreased amplitude in one (#16). The
N13 component was absent in one patient (#15). BAEPs were abnormal in five patients of
group 1 (#1,#3,#7,#15,#17) and in one of group 2 (#23). VEPs were normal in all patients. EEG
was normal in all patients but one (#5), who had fronto-central spikes during sleep but never
experienced seizures.
Table 1. Main characteristics of the 27 patients with LCH divided in two groups according to the presence of either MRI alterations specific for
ND-LCH (Group 1) or only of risk factors for ND-LCH (Group 2).
Group 1N = 17 Group 2N = 10 Difference(95%
confidence interval)p-
value
Gender 9 M, 8 F 7 M, 3 F
Median age at study entry (range) 8.2 years(1.7 to 27.5 years;
quartiles: 5, 8.2, 11.7 years)
10.2 years(3.7 to 16.4 yearsquartiles:
5.8, 10.2, 14.8 years)
-2.02 years(-8.97;4.6)
p = 0.688
Median time between the onset of LCH and
the first MRI evaluation
4.2 years 2.4 years 1.8 years(-1.3;5.1)
p = 0.248
Median time between the l onset of LCH
and the first observation of ND-LCH at MRI
4.2 years(quartiles: 0.8; 2.5; 4.2;
6.5; 14.5 years).
n.a.
Median age at onset s of LCH 2 years(range, 4 months -18
years;quartiles: 0.9, 2 and 3.3
years)
5.5 years(range, 18 months -15 years;
quartiles: 3.2, 5.5 and 9.5 years)
-3.years(-8.4;-0.7)p = 0.024
Multisystem vs. Single system 13 (76%) vs. 4 6 (60%) vs. 4 16%(-20;53%)p = 0.365
Reactivating or chronic active LCH 15 (88%) 6 (60%) 28%(6;62%)p = 0.088
Risk lesions for ND-LCH: Diabetes insipidus
/ Craniofacial lesions
11 / 6 6 / 5* Odds Ratio 1.53(0.32;
7.37)p = 0.591
Previous chemotherapy ongoing 15 (88%)7 (41%) 9(90%)4(40%) -2%(-26; 22%)p = 0.888/
1%(-37; 39%)p = 0.952
This is the Table 1 footnote.
* one patient had both risk factors
doi:10.1371/journal.pone.0131635.t001
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Neuropsychological assessment (S2 Table). Neuropsychological evaluation was normal
in all the 18 patients tested, with two exhibiting a discrepancy between verbal and non-verbal
performances (#2,#21). Two patients had a specific learning disorder (#10,#19).
Evaluation of the diagnostic performance of the diagnostic studies
Statistical analysis (Table 2, S3 Table and S4 Table). The best performance for prediction
of ND-LCH verified using MRI was observed for SEPs (ROC area = 0.85; 95%CI 0.66–0.96)
with high specificity and lower sensitivity (70%), followed by NE (ROC area = 0.71; 0.50–0.86).
When using ordinal grading MRI abnormalities, again SEPs had the best discrimination per-
formance (Harrell’s c = 0.80; 0.70–0.90). Defining a cut-off for the ordinal grading MRI abnor-
malities of 1, SEPs showed 82% specificity and 90% sensitivity.
Adding NE to the diagnostic protocol did not improve significantly the discrimination per-
formance, but there was an improvement in average sensitivity on ordinal grading MRI abnor-
malities over SEPs alone, and overall the integrated discrimination improved by 7.6% (-6%;
+21%). Based on previous findings, we defined a diagnostic protocol including SEPs and NE to
assess whether patients with ND-LCH can be predicted as such prior to MRI. Both tests can be
negative or positive or only one of the two can be positive. On the basis of these three thresh-
olds, we calculated sensitivity and specificity area under the ROC curve.
Follow-up studies (Table 3)
Wemonitored clinical, MRI and neurophysiological changes in patients with ND-LCH. All
patients but two (#5 and 7) of group 1 underwent repeated evaluations including MRI, MRS,
Table 2. Sensitivity and specificity, ROC area, PPV, NPV, number of patients of NE, BAEPs, SEPs, MRS, NPS for diagnostic test of MRI and grading
of MRI ND-LCH.95%Confidence Intervals in parentheses.
Sensitivity Specificity ROC area PPV NPV N° patients
MRI
NE 52.9%(27.8%-77.0%) 90.0%(55.5%-99.7%) 0.71(0.50–0.86) 90.0%(55.5%-99.7%) 52.9%(27.8%-77.0%) 27
BAEPs 29.4%(10.3%-56.0%) 90.0%(55.5%-99.7%) 0.60(0.39–0.78) 83.3%(35.9%-99.6%) 42.9%(21.8%-66.0%) 27
SEPs 70.6%(44.0%-89.7%) 100.0%(69.2%-100%)* 0.85(0.66–0.96) 100.0%(73.5%-100%)* 66.7%(38.4%-88.2%) 27
MRS 52.9%(27.8%-77.0%) 90.0%(55.5%-99.7%) 0.71(0.50–0.86) 90.0%(55.5%-99.7%) 52.9%(27.8%-77.0%) 27
NPS# 22.2%(2.8%-60.0%) 71.4%(29.0%-96.3%) 0.47(0.20–0.70) 50.0%(6.8%-93.2%) 41.7%(15.2%-72.3%) 16
Grading of MRI cut-off grading level > 1
NE 80.0%(44.4%-97.5%) 88.2%(63.6%-98.5%) 0.84(0.66–0.96) 80.0%(44.4%-97.5%) 88.2%(63.6%-98.5%) 27
BAEPs 30.0%(6.7%-65.2%) 82.5%(56.6%-96.2%) 0.56(0.35–0.75) 50.0%(11.8%-88.2%) 66.7%(43.0%-85.4%) 27
SEPs 90.0%(55.5%-99.7%) 82.4%(56.6%-96.2%) 0.86(0.66–0.96) 75.0%(42.8%-94.5%) 93.3%(68.1%-99.8%) 27
MRS 50.0%(18.7%-81.3%) 70.6%(44.0%-89.7%) 0.60(0.39–0.78) 50.0%(18.7%-81.3%) 70.6%(44.0%-89.7%) 27
NPS# 14.3%(0.4%-57.9%) 66.7%(29.9%-92.5%) 0.40(0.15–0.65) 25.0%(0.6%-80.6%) 50.0%(21.1%-78.9%) 16
This is Table 2 footnote.
BAEPs: brainstem auditory evoked potentials; MRI: Magnetic Resonance imaging; MRS: Magnetic Resonance Spectroscopy; NE: neurological
examination; NPS: neuropsychological evaluation; NPV: negative predictive value;PPV, positive predictive value; ROC: Receiver operating characteristic;
SEPs: somatosensory evoked potentials; VEPs: visual evoked potentials.
#: Neuropsychological evaluation was performed in 16 out of 27 patients either for patient’s refusal or because no neuropsychologist was available the
date of planned evaluation.
(*) one-sided, 97.5% confidence interval
doi:10.1371/journal.pone.0131635.t002
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Table 3. Neurological, neurophysiological, radiological assessment of patients in Group 1 at short term follow-up.
Pt Time
interval
(months)
NE BAEPs SEPs MRI/grading MRS
1 0 Slight tremor at nose-finger test (SARA:1) Bil increased I-V
interval
L N20 delayed
latency
Cerebellum/1 N
12 Slight tremor at nose-finger test (SARA:1) Bil increased I-V
interval
L N20 delayed
latency and
abnormal
waveform
Cerebellum/1 N
2 0 R deafness, L clonus, mild ataxia (SARA: 2) N L N20 abnormal
waveform and
decreased
amplitude
Cerebellum,sWM,
brainstem/2
N
42 Slight tremor at nose-finger test, clonus in the left lower limb,
enhanced deep tendon reflexes, R deafness (SARA: 2)
Right increased
I-V interval
Bil N20 delayed
latency
Cerebellum,sWM,
brainstem/2
N
3 0 Slight ataxia (SARA:1) Bil increased I-V
interval
N Cerebellum,
brainstem/3
N
15 Slight ataxia (SARA:1) Abnormal R V
component
waveform
N Cerebellum,
brainstem/3
N
4 0 Clonus and enhanced deep tendon reflexes in the lower limbs
(SARA:0)
N Bil N20 decreased
amplitude
Cerebellum,sWM/
2
Ab
14 Slight hemiparesis, clonus and enhanced deep tendon
reflexes in the lower limbs (SARA:0)
N L absent N20 Cerebellum,sWM/
2
Ab
5 0 L arm weakness, left dysmetria, nystagmus (SARA: 4) N R N20 abnormal
waveform and
decreased
amplitude
Cerebellum,sWM,
brainstem/3
Ab
NA NA NA NA NA NA
6 0 N (SARA:0) N N Cerebellum/1 N
34 Bilateral slight tremor at nose-finger test, clonus in the left
lower limb, R enhanced deep tendon reflexes (SARA:1)
N Right N20
decreased
amplitude
Cerebellum/1 N
7 0 Tetraparesis, dysphonia, dysphagia, dysarthria (SARA:39) IV and V abnormal
waveforms on the
R side
Bil absent P14 e
N20 responses
Cerebellum,sWM,
BG, brainstem/4
Ab
50 Impaired consciousness, worsening of dysarthria and
dysphagia
NA NA Cerebellum,sWM,
BG, brainstem/4
Ab
8 0 N (SARA:0) N BilN20 delayed
latency
Cerebellum/4 Ab
17 NA N BilN20 delayed
latency
Cerebellum/4 Ab
9 0 N (SARA:0) N Bil N20 delayed
latency
Cerebellum,sWM,
brainstem/3
Ab
33 N (SARA:0) N Bil N20 delayed
latency (worsened)
Cerebellum,sWM,
brainstem/3
Ab
10 0 N N Bil delayed N20
latency
Cerebellum,sWM/
1
Ab
24 Slight tremor and dysmetria at nose-finger test (R>L), clonus
and enhanced deep tendon reflexes in the lower limbs (R> L)
(SARA:1)
N R N20 decreased
amplitude, L
absent N20
Cerebellum,sWM/
1
Ab
11 0 N (SARA:0) N N Cerebellum/1 N
22 N (SARA:0) N N Cerebellum/1 Ab
12 0 N (SARA:0) N N (N20 at upper
limits)
Cerebellum,
sWM/2
N
(Continued)
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NE, BAEPs and SEPs. We excluded VEPs and EEG due to their low sensitivity. In patient #7
EPs were not re-evaluated as already severely impaired at the first evaluation; patient #5 was
lost from the follow-up.
The median follow-up duration was 24 months (range, 8–50 months). In five patients(#1, 3,
11–13) neurophysiological and neurological findings remained unchanged. A worsening of EP
results was observed in eight patients (#2, 4, 6, 8–10, 16,17), five of which (#2, 6, 8–10) also
showed neurological worsening.
In patient #14 neurological symptoms worsened without EP impairment. In patient #15
SEPs slightly improved.
MRI remained unchanged in all patients but one (#14) in whom a progression of white mat-
ter and globus pallidus abnormalities was observed. MRS findings appeared modified in two
(#11, 13) patients.
Table 3. (Continued)
Pt Time
interval
(months)
NE BAEPs SEPs MRI/grading MRS
30 N (SARA:0) N N (N20 at upper
limits)
Cerebellum,
sWM/2
N
13 0 N (SARA:0) N N Cerebellum,
sWM/1
Ab
33 N (SARA:0) N N Cerebellum,
sWM/1
N
14 0 R tremor and dysmetria at nose-finger test (SARA:2) N R N20 slight
reduction
Cerebellum,sWM,
BG, Brainstem /2
N
23 Bil tremor and dysmetria at nose-finger test (SARA:2) N R N20 slight
reduction
Worsening in
sWM and BG,
Cerebellum/2
N
15 0 Dysarthria, dysphagia, ataxia, bradykinesia, hypertonus, slight
R hemiparesis, dysmetriaatnosefingertest (R>L),
clonusandenhanceddeeptendonreflexes (R> L) (SARA:14)
Bil increased I-V
interval
Bil absent N13,
P14 and N20
Cerebellum,
brainstem/4
Ab
8 Dysarthria, ataxia, bradykinesia, hypertonus, slight R
hemiparesis, dysmetriaatnosefingertest (R>L),
clonusandenhanceddeeptendonreflexes (R> L).
Dysphagiaimprovement (SARA:14)
Bil increased I-V
interval (R>L)
Bil absent N20 Cerebellum,
brainstem/4
Ab
16 0 Ldysmetria and tremor at nose-finger test, R clonus (SARA:2) N L P14 and N20
decreased
amplitude
Cerebellum,sWM/
2
N
40 Bildysmetria and tremor at nose-finger test, L dysmetria at the
heel-shin slide (SARA:2,5)
Bil increased I-V
interval
R absent N20, L N
20 delayed latency
Cerebellum,sWM/
2
N
17 0 N (SARA: NA) Increased I-V
interval on the R
side
N Cerebellum/1 Ab
24 N (SARA: 0) BilIncreased I-V
interval
N Cerebellum/1 Ab
This is Table 3 footnote.
Ab: abnormal; BAEPs: brainstem auditory evoked potentials; BG: basal ganglia; Bil: bilateral; EEG: electroencephalogram; FSIQ: full scale intelligence
quotient; L: left; MRI: Magnetic Resonance imaging; MRS: Magnetic Resonance Spectroscopy; N: normal; NA: not available; NE: neurological
examination; NP: not performed; NPS: neuropsycological evaluation; PIQ: performance intelligence quotient; R: right; SARA: Scale for the Assessment
and Rating of Ataxia; SEPs: somatosensory evoked potentials; SLD: specific language disorder; sWM: supratentorial white matter; VEPs: visual evoked
potentials; VIQ: verbal intelligence quotient.
doi:10.1371/journal.pone.0131635.t003
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Discussion
We applied a multidisciplinary diagnostic protocol for assessing and following-up patients
with early-stage ND-LCH. In this study,an extended structural MRI protocol allowed to iden-
tify neurodegenerative abnormalities in patients at risk for ND-LCH before neurological
impairment and neurophysiological abnormalities became obvious. This result is of relevance
as brain MRI is not routinely performed in patients at risk for ND-LCH and targeted MRI pro-
tocols to detect neurodegenerative abnormalities have not been developed yet. MRI abnormali-
ties in patients with ND-LCH have been described since 2000 [6, 9]. This same pattern is
confirmed in our series, with the cerebellum being the most frequent and earliest site of
involvement, sometimes in association to brainstem, basal ganglia and hemispheric white mat-
ter. We also confirmed the lack of concordance between the degree of neurological impairment
and the topography, extent and grading of the neurodegenerative lesions in most patients [16,
27].
While structural MRI appears to be the reference standard, SEPs is the test with the highest
capability to predict ND-LCH and discriminate its grading. Remarkably, SEPs were abnormal
also in patients with noneurological signs or who only exhibited subtle deficits. In two previous
studies on patients with ND-LCH, which included VEPs, EEG and BAEPs, abnormal EPs were
found in up to 40% of patients[15, 19]. In our study, 82% of patients with ND-LCH had some
kind of EP abnormality. This discrepancy is related to the use of SEPs, as the remaining evoked
potentials modalities were less contributive. VEPs were normal in all patients with ND-LCH;
only one patient had mild EEG abnormalities during sleep but never had seizures; although
BAEPs turned out to be more sensitive than SEPs in selected cases, their overall predictive
value was lower. In contrast to previous observations[19, 21], none of our patients had cogni-
tive impairment or working memory deficits.
We noticed that subtle abnormalities may be difficult to identify in a single patient in the
early pre-symptomatic stages. Regarding this issue, the combination of neurological examina-
tion, targeted MRI protocols, and SEPs had the highest diagnostic value. MRS might provide
interesting correlations between morphology and function. A decreased peak of N-acetyl-
aspartate in the cerebellum of patients with ND-LCH was described in single case reports[28,
29]. In our study, spectroscopy showed high sensitivity and specificity in identifying patients
with ND-LCH and disclosed abnormalities also in patients with minor or no neurological defi-
cits. In the short term follow-up, structural MRI remained unchanged in all but one patient in
whom neurological manifestations had worsened. MRS modifications appeared in two
patients, suggesting that MRS may usefully integrate structural MRI.
During follow-up we also identified neurological and neurophysiological changes in most
patients with ND-LCH, despite structural brain MRI did not show signs of progression. An
integrated neurophysiological and neurological protocol appears necessary to monitor the pro-
gression of the disease, also in view of possible new therapeutic approaches. Yet, limited knowl-
edge of the pathogenic mechanism of demyelination, without any available animal model of
ND-LCH, has impaired our ability to interpret MRI alteration and their changing over time
[5].
Recent studies of large cohorts of patients in the prospective trials LCH I to III have shown
that a younger age at diagnosis does not represent an independent, adverse prognostic factor
for treatment response and survival[30–32]. In our study, patients with ND-LCH had a signifi-
cantly younger median age at the onset of LCH than those without neurodegenerative alter-
ations. Since the time elapsed from the onset of LCH to the first MRI evaluation was similar in
patients with and in those without ND-LCH, our findings suggest that the risk of developing
ND-LCH does not depend on the duration of the disease only. It can be hypothesized that a
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subset of patients with LCHmight be individually prone to develop “early onset LCH” followed
by ND-LCH. Whether genetic polymorphisms in still undefined genes may play a role in the
development of LCH, and of ND-LCH in particular, remains an open issue[5, 33]. Addition-
ally, the hypothesis that LCH may be induced or at least triggered by a viral infection has been
recently emphasized after elevated amounts of Merkel cell polyomavirus DNA were found in
the peripheral blood cells of patients with LCH[34]. Whether neurodegeneration may be a late
manifestation of the viral pathogen in LCH also remains an open issue[5].
The main unmet medical need in ND-LCH remains treatment. Since reversal of clinical
manifestations in patients with overt impairment is unrealistic, hopes should point to an early
start of a potentially effective therapy. Our multidisciplinary approach can allow to identify
asymptomatic or pauci-symptomatic patients with ND-LCH in order to start treatment early
and possibly improve prognosis. A longitudinal therapeutic study is currently ongoing in our
center and will hopefully help solve this issue. The possible therapeutic use of target therapy at
least in the subset of patients with V600EBRAF mutation should be carefully explored in a sci-
entific setting[35].
Our study has limitations. The number of patients is relatively small; yet, given the rarity of
the disease, and especially of ND-LCH, recruiting a larger number of patients would have
needed a very long time or a multicenter setting, thus introducing additional potential biases.
We also acknowledge that a study limited to prospective observation of newly diagnosed
patients with LCH could have helped in describing the natural history of the disease, but this
might require an extremely long time interval, which would impair feasibility. A correlation
between time of follow-up and the probability to observe ND-LCH has been proposed [16]. To
this issue, it is relevant that the duration of the disease was comparable between patients in
group 1 and those in group 2, thus confirming that patients at risk but who did not show
ND-LCH were not simply observed too early, at least compared to those with ND-LCH.
Conclusions
We propose a novel protocol of evaluation for patients with LCH, with the main purpose of
identifying and monitoring patients with ND-LCH while still in a pre- or pauci-symptomatic
stage. Patients with ND-LCH deserve a targeted structural MRI study for early identification of
demyelination. Spectroscopy may then usefully complement structural MRI. SEPs are promis-
ing in detecting initial brain dysfunction. The combined use of SEPs and careful neurological
evaluation may represent a valuable, low-cost, well-tolerated and easily available methodology
to monitor patients from pre-symptomatic to symptomatic stages of ND-LCH. The wider use
of our multidisciplinary protocol might allow the selection of patients for early therapeutic
intervention, hopefully providing the basis for future therapeutic trials.
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